Published in Diabetologia on December 01, 1995
Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy | NCT01313117
Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev (2008) 5.74
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol (2005) 2.88
Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal (2010) 2.11
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta (2009) 2.05
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care (2009) 1.49
Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan (2014) 1.45
Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Investig (2011) 1.25
Reactive oxygen species: impact on skeletal muscle. Compr Physiol (2011) 1.14
Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Investig (2010) 1.11
Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol (2011) 1.11
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Mult Scler (2010) 1.00
Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud (2009) 1.00
Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurol Clin (2013) 0.99
α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS One (2013) 0.97
The conductor of the autonomic orchestra. Front Endocrinol (Lausanne) (2012) 0.96
Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med (2008) 0.95
Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J (2010) 0.92
Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr (2014) 0.90
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol (2010) 0.89
Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice. Rheumatol Int (2006) 0.88
Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag (2011) 0.87
Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol (2012) 0.87
Role of nitrosative and oxidative stress in neuropathy in patients with type 2 diabetes mellitus. J Neurosci Rural Pract (2012) 0.87
Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol (2011) 0.86
Relationships between Brachial-Ankle Pulse Wave Velocity and Peripheral Neuropathy in Type 2 Diabetes. Diabetes Metab J (2012) 0.85
Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis (2011) 0.85
Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes (2011) 0.85
Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med (2011) 0.84
Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat (2014) 0.84
Lack of interaction between thioctic acid, glibenclamide and acarbose. Br J Clin Pharmacol (1999) 0.83
Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther (2012) 0.83
Reduction of ischemia reperfusion injury after liver resection and hepatic inflow occlusion by alpha-lipoic acid in humans. World J Gastroenterol (2006) 0.83
Transcriptional regulation of fibroblast growth factor 21 expression. Endocrinol Metab (Seoul) (2014) 0.81
Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes. Rev Diabet Stud (2013) 0.80
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. J Diabetes Res (2016) 0.80
Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. Int J Mol Sci (2014) 0.78
Dietary supplements in the management of hypertension and diabetes - a review. Afr J Tradit Complement Altern Med (2014) 0.77
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine. Psychopharmacology (Berl) (2014) 0.76
Dyslipidemia as a contributory factor in etiopathogenesis of diabetic neuropathy. Indian J Endocrinol Metab (2011) 0.76
Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics. J Med Life (2015) 0.75
Fabrication of an alpha-lipoic acid-eluting poly-(D,L-lactide-co-caprolactone) cuff for the inhibition of neointimal formation. Exp Mol Med (2009) 0.75
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther (2016) 0.75
Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. World J Clin Cases (2016) 0.75
State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol (2010) 0.75
Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol (2014) 0.75
Alpha-lipoic acid does not acutely affect resistance and conduit artery function or oxidative stress in healthy men. Br J Clin Pharmacol (2004) 0.75
Effects of lipoic acid on growth and biochemical responses of common carp fed with carbohydrate diets. Fish Physiol Biochem (2016) 0.75
Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model. Psychopharmacology (Berl) (2017) 0.75
Dietary alpha lipoic acid supplementation prevents synovial inflammation and bone destruction in collagen-induced arthritic mice. Rheumatol Int (2010) 0.75
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) 2.82
A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. European NIDDM Policy Group. Diabet Med (1994) 2.78
Membrane potential of beta-cells in pancreatic islets. Pflugers Arch (1974) 2.74
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care (2000) 2.59
Significance of ionic fluxes and changes in membrane potential for stimulus-secretion coupling in pancreatic B-cells. Experientia (1984) 2.43
Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view. Diabet Med (1988) 2.27
Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic B cells. Biochem Pharmacol (1982) 1.90
Electrophysiological evidence for coupling between beta cells of pancreatic islets. Nature (1976) 1.86
Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care (1997) 1.84
Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med (1992) 1.80
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism (2002) 1.68
Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet (1993) 1.68
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
The kinetics of electrical activity of beta cells in response to a "square wave" stimulation with glucose or glibenclamide. Horm Metab Res (1976) 1.55
Electrical characteristics of the beta-cells in pancreatic islets. J Physiol (Paris) (1976) 1.53
Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med (1993) 1.51
Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis. Diabetologia (1995) 1.48
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia (1998) 1.47
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care (1999) 1.46
Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med (1998) 1.43
[Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes]. Dtsch Med Wochenschr (1999) 1.40
Changes in brainstem auditory evoked potentials during insulin-induced hypoglycaemia in type 1 diabetic patients. Diabet Med (1991) 1.39
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab (2004) 1.39
Exercise-induced fall of blood glucose in insulin-treated diabetics unrelated to alteration of insulin mobilization. Diabetes (1979) 1.33
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia (2005) 1.29
Assessment of small and large fiber function in long-term type 1 (insulin-dependent) diabetic patients with and without painful neuropathy. Pain (1988) 1.28
The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications (1992) 1.27
Smoking--a trigger for chronic inflammation and cancer development in the pancreas. Am J Gastroenterol (2006) 1.24
The ionic, electrical, and secretory effects of endogenous cyclic adenosine monophosphate in mouse pancreatic B cells: studies with forskolin. Endocrinology (1984) 1.23
Effects of amino acids on membrane potential and 86Rb+ fluxes in pancreatic beta-cells. Am J Physiol (1981) 1.19
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res (1999) 1.19
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev (2005) 1.18
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med (2005) 1.17
Cyclic variations of glucose-induced electrical activity in pancreatic B cells. Pflugers Arch (1982) 1.17
Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia (1977) 1.17
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol (2002) 1.16
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care (1999) 1.16
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results. Monogr Atheroscler (1985) 1.15
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes (1997) 1.13
Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes (1999) 1.13
Visceral afferent neuropathy in diabetic gastroparesis. Diabetes Care (1991) 1.13
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. Horm Metab Res (2007) 1.12
Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest (1990) 1.11
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med (2013) 1.08
Evaluation of thermal, pain, and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J Neurol Neurosurg Psychiatry (1988) 1.06
Potassium dependence of the membrane potential of pancreatic B-cells. FEBS Lett (1978) 1.05
Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol (1994) 1.05
Noninvasive blood glucose sensors based on near-infrared spectroscopy. Artif Organs (1994) 1.04
Hepatic production of VLDL-triglycerides. Dependence of portal substrate and insulin concentration. Horm Metab Res (1980) 1.04
Dietary-induced hypertrophic--hyperplastic obesity in mice. J Lipid Res (1974) 1.04
Metabolic diseases and their possible link to risk indicators of periodontitis. J Periodontol (2000) 1.03
DSD-1-proteoglycan is the mouse homolog of phosphacan and displays opposing effects on neurite outgrowth dependent on neuronal lineage. J Neurosci (1999) 1.02
[13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia (1996) 1.01
Nutritional intake of 2868 IDDM patients from 30 centres in Europe. EURODIAB IDDM Complications Study Group. Diabetologia (1996) 1.01
Insulin release, cGMP, cAMP, and membrane potential in acetylcholine-stimulated islets. Am J Physiol (1978) 1.01
Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia (1985) 0.98
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr (2009) 0.97
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation (1993) 0.97
Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes (1997) 0.96
Forskolin, an activator of adenylate cyclase, increases CA2+-dependent electrical activity induced by glucose in mouse pancreatic B cells. Endocrinology (1983) 0.96
Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia (2002) 0.96
Glucose-induced changes of the membrane potential of pancreatic B-cells: their significance for the regulation of insulin release. Adv Exp Med Biol (1979) 0.95
Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. Horm Metab Res (1997) 0.95
Dibutyryl cyclic AMP triggers Ca2+ influx and Ca2+-dependent electrical activity in pancreatic B cells. Biochem Biophys Res Commun (1983) 0.95
Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry (1990) 0.95
The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med (1993) 0.94
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta (1995) 0.94
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med (1999) 0.94
Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab (1993) 0.94
An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther (2008) 0.94
9-Aminoacridine- and tetraethylammonium-induced reduction of the potassium permeability in pancreatic B-cells. Effects on insulin release and electrical properties. Biochim Biophys Acta (1979) 0.94
Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis (1983) 0.93
Blood amine acid levels in patients with insulin excess (functioning insulinoma) and insulin deficiency (diabetic ketosis). Metabolism (1978) 0.93
Electrogenic sodium pump in beta-cells of islets of Langerhans. J Physiol (1975) 0.92
HLA antigens and immunoresponsiveness to insulin in insulin-dependent diabetes mellitus. Tissue Antigens (1976) 0.92
Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment. Diabetes (1988) 0.92
The natural course of peripheral and autonomic neural function during the first two years after diagnosis of type 1 diabetes. Klin Wochenschr (1988) 0.91
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes (1998) 0.91
Glucose metabolism in perfused skeletal muscle. Demonstration of insulin resistance in the obese Zucker rat. Biochem J (1979) 0.91
Work absenteeism in type 2 diabetes mellitus: results of the prospective Diabetes Intervention Study. Diabete Metab (1993) 0.91
The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes (2004) 0.90
Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab (1993) 0.89
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol (2013) 0.89
Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia (1991) 0.89
The electrical activity of pancreatic beta-cells of diabetic mice. FEBS Lett (1976) 0.89